- ALX Oncology Appoints Allison Dillon as Chief Business Officer
- ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
- ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
- ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
- ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- ALX Oncology Announces November Investor Conference Participation
- ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.68 |
---|---|
High | 17.83 |
Low | 15.47 |
Bid | 17.05 |
Offer | 17.60 |
Previous close | 15.78 |
Average volume | 663.04k |
---|---|
Shares outstanding | 50.50m |
Free float | 39.73m |
P/E (TTM) | -- |
Market cap | 886.76m USD |
EPS (TTM) | -3.74 USD |
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.
More ▼